1 **Title:**

2 Immune checkpoint inhibitor response in sarcomas associates with immune infiltrates and

- 3 increased expression of transposable elements and viral response pathways
- 4 5

6 **Authors and Affiliations:**

- 7 Benjamin A. Nacev^{1,2,*,#,**}, Martina Bradic^{1,3,*}, Hyung Jun Woo³, Allison L. Richards³, Ciara M.
- 8 Kelly^{1,2}, Mark A. Dickson^{1,2}, Mrinal M. Gounder^{1,2}, Mary L. Keohan^{1,2}, Ping Chi^{1,2}, Sujana
- 9 Movva^{1,2}, Robert Maki^{1,2}, Emily K. Slotkin^{1,2}, Evan Rosenbaum^{1,2}, Viswatej Avutu^{1,2}, Jason E.
- 10 Chan^{1,2}, Lauren Banks^{1,2}, Travis Adamson^{1,2}, Samuel Singer⁵, Cristina R. Antonescu⁶, William
- 11 D. Tap^{1,2}, Mark T.A. Donoghue^{3,†}, Sandra P. D'Angelo^{1,2,†}
- 12
- ¹³ ¹Department of Medicine, Memorial Sloan Kettering Cancer Center, Manhattan, New York
- 14 ²Weill Cornell Medical College, New York, NY
- ¹⁵ ³Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering
- 16 Cancer Center, New York, NY
- 17 ⁴Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
- 18 ⁵Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
- ¹⁹ ⁶Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
- 20 *Equal contribution
- 21 †Equal contribution
- 22 #Correspondence
- 23 **Current affiliations: Department of Medicine and Department of Pathology University of
- 24 Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; UPMC Hillman Cancer Center,
- 25 Pittsburgh, Pennsylvania26
- 27

28 Manuscript Information:

- 29 Main text figures: 4
- 30 Extended Data Figures: 9
- 31 Extended Data Tables: 3

33 ABSTRACT

34 Response to immune checkpoint inhibition (ICI) in sarcoma is overall low and heterogeneous. 35 Understanding determinants of ICI outcomes may improve efficacy and patient selection. One 36 potential mechanism is epigenetic de-repression of transposable elements (TEs), which 37 stimulates antitumor immunity. Here, we used transcriptomic data to assign immune-hot versus 38 immune-cold status to 67 pre-treatment biopsies of sarcomas from patients treated on ICI trials. 39 Progression-free survival and overall response was superior in the immune-hot group. Expression 40 of TEs and epigenetic regulators significantly predicted immune-hot status in a regression model 41 in which specific TE subfamilies and IKZF1, a chromatin-interacting transcription factor, were 42 significantly contributory. TE and IKZF1 expression positively correlated with tumor immune 43 infiltrates, inflammatory pathways, and clinical outcomes. Key findings were confirmed in a 44 validation cohort (n=190). This work suggests that TE and *IKZF1* expression warrant investigation 45 as predictive biomarkers for ICI response and as therapeutic targets in sarcomas.

47 **INTRODUCTION**

48 Sarcomas are a diverse group of more than 170 histologic entities¹ that derive from tissues of 49 mesenchymal origin. The underlying genetic causes of sarcomas^{2,3} are diverse and their biologic 50 and pathologic behavior is highly varied⁴. The clinical management of metastatic sarcomas is 51 generally palliative and relies upon systemic therapies including cytotoxic chemotherapy, targeted 52 therapies, and in some instances immune checkpoint blockade⁵. The overall response rate to 53 first-line chemotherapy in soft tissue sarcoma is approximately 20%⁶. Hence, there is a need for 54 both new treatment modalities and improved methods to select patients most likely to respond to 55 specific treatments.

56

57 Immune checkpoint inhibition (ICI) has been studied in sarcomas, and activity has been noted 58 with nivolumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4)⁷ or with 59 pembrolizumab (anti-PD-1) as a single agent⁸. Efforts to enhance the activity of ICI through 60 combination with other immune-modulatory drugs or with cytotoxic therapies has revealed 61 variable response rates, which likely depend on the drug combination and sarcoma subtype 62 (recently reviewed⁹). In parallel, predictive biomarkers for ICI response in sarcoma are being 63 explored. While microsatellite instability (MSI) and high tumor mutation burden (TMB) predict 64 response in carcinomas¹⁰⁻¹⁶, TMB is relatively low in sarcomas and MSI is exceedingly rare¹⁷. 65 Alternative biomarkers such as tertiary lymphoid structures and B cell and CD8+ T cell infiltrates 66 correlate with ICI response in some soft tissue sarcomas such as undifferentiated pleomorphic 67 sarcoma (UPS)^{2,18,19}.

68

Another potential determinant and predictor of antitumor immunity and ICI response are epigenetic states, which are determined by chemical modifications of DNA, RNA, and DNAassociated proteins together with their positioning relative to specific genomic sequences²⁰. One key function of epigenetic states is to regulate transcriptional programs, including those that

influence immune signaling. Therefore, genetic or pharmacologic perturbation of the machinery that establishes or maintains epigenetic states can prime ICI response in preclinical models and correlates with ICI clinical response²¹⁻²⁹. For example, epigenetic mechanisms can promote immune escape through repression of antigen-presenting machinery and transposable elements (TEs), epigenetically silenced sequences of viral origin that, when de-repressed, stimulate antiviral immune signaling^{22,24,30}.

79

80 We therefore hypothesized that sarcoma baseline immune infiltrates and clinical outcomes 81 following immunotherapy treatment are influenced by expression of TEs and epigenetic 82 regulators. To test this, we generated and analyzed transcriptomic profiles of pre-treatment 83 biopsies from 67 unique patients enrolled in 3 ICI trials at our institution and an independent 84 validation cohort. Here, we demonstrate that the efficacy of ICIs is linked to the de-repression of 85 TEs that are normally silenced by epigenetic mechanisms and upregulation of the transcription 86 factor IKZF1, which interacts with chromatin-modifying complexes. TE and *IKZF1* upregulation in 87 turn correlate with hallmarks of tumor-intrinsic innate immune activation such as type I interferon 88 and antigen presentation, suggesting a potential mechanism for enhanced immune response 89 mediated by tumor epigenetic states.

90

91 Results

92

Baseline immune cell populations predict response and progression-free survival in sarcoma patients treated with immune checkpoint inhibitors

95 To study the influence of features linked to epigenetic states on antitumor immunity, we first 96 characterized baseline immune infiltrates in tumor biopsies from 67 patients with a heterogeneous 97 set of sarcomas (>10 subtypes) who were subsequently treated on ICI clinical trials (**Extended**

98 **Data Table 1**). Twelve patients responded to ICI and 55 did not (CR/PR=12, SD=21, PD=34). 99 Baseline samples were analyzed to identify tumor characteristics that could be informative prior 100 to treatment and to eliminate confounding by varying ICI drugs and combinations used across 101 trials. We employed an RNA sequencing (RNA-seq)-based method to quantify the abundance of 102 different immune populations, MCP-counter³¹. To obtain robust clustering of samples based on 103 their profile of immune infiltrates, we used a hierarchical clustering of principal components 104 (HCPC) approach³², which integrates principal components (PCA) and hierarchical clustering. 105 This HCPC revealed two highly distinct groups, which we deemed "immune-cold" and "immune-106 hot" (Figure 1A, B; Extended Data Figure 1). Except for cancer-associated fibroblasts, all cell 107 types defined by MCP-counter were significantly associated with cluster partitioning, with T cells 108 $(p=3.41 \times 10^{-10})$ contributing the most, followed by cytotoxicity score (representative of cytotoxic 109 lymphocytes) (p=2.01 x 10⁻⁹), and CD8⁺ T cells (p=6.89 x 10⁻⁹), NK cells (p=3.54 x 10⁻⁸), B cells 110 $(p=3.58 \times 10^{-8})$, neutrophils $(p=9.12 \times 10^{-8})$, myeloid dendritic cells $(p=1.17 \times 10^{-7})$, 111 macrophage/monocytes (p=1.34 x 10⁻⁷), and endothelial cells (p=7.88 x 10⁻³). The immune-hot 112 cluster displayed, on average, greater abundance of all immune cell types in comparison to the 113 overall mean, and conversely the immune-cold cluster displayed lower abundance of the same 114 immune cell types (Extended Data Table 2).

115

116 Having assigned tumors to hot and cold immune groups, we next determined how these immune 117 states correlated with clinical outcomes after the 67 patients in our cohort received ICI-based intervention in one of 3 clinical trials: pembrolizumab plus talmogene laherparepvec 118 119 (NCT03069378)³³, nivolumab plus bempegaldesleukin (NCT03282344)², and pembrolizumab 120 plus epacadostat (NCT03414229)³⁴. There were no significant differences between the 3 ICI trials 121 with respect to the number of responders and non-responders or immune-hot and -cold patients 122 (Extended Data Table 3). We compared overall response rates (ORR) by RECIST version 1.1³⁵ 123 in immune-hot (ORR=30% [9/30]) vs. immune-cold (ORR=8.1% [3/37]) tumors. The ORR in the

124	immune-hot group was significantly greater than in the immune-cold group (Fisher's Exact Test,
125	95% CI 1.03-30.31, p=0.02). Furthermore, the immune hot samples were more prevalent than the
126	immune cold samples in the complete response (CR) compared to progressive disease (PD)
127	groups (Fisher's Exact Test, 95% CI 0.02-0.73, p=0.01), while there was no significant difference
128	in the CR versus stable disease (SD) and SD versus PD. The expression levels of immune
129	checkpoint-related genes were consistent with the patterns observed in immune infiltrates, with
130	elevated expression of CD274 (PD-L1), CTLA4 (two-sided t-test, p= 1.83 x 10 ⁻⁶ and p=1.18 x 10 ⁻⁶
131	⁴ , respectively), and <i>LAG3</i> (two-sided t-test, p=0.12) in immune-hot tumors (Figure 1C).

132

To determine if the baseline immune type was prognostic for progression-free survival (PFS), we performed survival analysis including the histologic sarcoma subtype as a covariate (**Figure 1D**, **Extended Data Figure 2**). Median PFS among patients with immune-cold tumors was 1.7 months vs. 3.65 months for immune-hot. Tumor classification as immune-hot contributed to improved PFS (HR=0.43, 95% CI 0.22-0.84, p=0.01) (**Extended Data Figure 2**). The histologic subtypes of leiomyosarcoma, myxofibrosarcoma, osteosarcoma, and small blue round cell tumors had a significant effect on PFS in our cohort.

140

Hot and cold immune types are analogous to previously identified sarcoma immuneclasses

To determine how the two immune subtypes identified in this study relate to previously described sarcoma immune classes (SICs), which correlate with immune infiltrates and ICI response, we classified our samples according to those 5 SIC clusters (labeled A-E, **Extended Data Figure 3**)¹⁹. In total, 47% (14/30) of the immune-hot samples from our study fell into immune-hot SICs D and E. The remaining 53% (16/30) of immune-hot samples were assigned to immune-cold SIC B. In contrast, the immune-cold samples from our study were almost exclusively classified into immune-cold SICs A and B, with only two samples matching SIC C (**Extended Data Figure 3**).

In summary, the two distinct immune clusters identified in this study between which we observe differences in PFS and ORR following ICI treatment are associated with SICs that are consistent with immune-high and immune-low states.

153

154 In addition to the validation of our clustering through comparison with independently developed 155 classifications, we also reasoned that if the immune type clusters identified in our approach via 156 deconvolution of bulk RNA sequencing accurately reflected immune cell populations, then the 157 immune-hot cluster should contain more immune infiltrates than the immune-cold cluster, 158 resulting in lower tumor content. Concordantly, the immune-hot type displayed significantly lower 159 purity compared to the immune-cold type (two-sided t-test; t=-3.11, df=64, p=2.7 x 10-3) 160 (Extended Data Figure 4A). To further confirm this relationship, we performed a permutation test 161 randomly assigning samples to immune groups and comparing the difference between purity 162 estimates between the two groups, which was repeated 10,000 times to produce a null 163 distribution. The observed data displayed significantly greater differences in tumor purity 164 estimates compared with the null distribution (p=3.1 x 10⁻³) (**Extended Data Figure 4B**). Lastly, 165 tumor purity was inversely correlated with lymphoid and myeloid cell content (Extended Data 166 Figure 4C), which is consistent with immune cell content contributing to the non-tumor cell 167 fraction.

168

169 **TE and Ikaros (***IKZF1***) expression predict immune types in sarcoma**

Although the activation of immune response through increased expression of transposable elements (TEs) and the involvement of epigenetic genes in the regulation of TE expression has been established in many cancers^{23,24,36-39}, these processes have not been well studied in sarcoma. Our analysis of expression of 1,002 intergenic TEs across the two immune types shows heterogenous expression (**Extended Data Figure 5**). Thus, we next asked if expression of TEs and epigenetic regulators is predictive of tumor immune types in sarcoma. Lasso logistic

176 regression models including expression of TEs (R^2 =0.29), epigenetic regulators (R^2 =0.19) had 177 higher R^2 values, indicating that the models including these features are a better fit for the 178 prediction of immune type than a basic model that included only sarcoma subtypes and 179 sequencing batch or models of TE and epigenetic regulator expression with randomized immune 180 type sample labels (R^2 TE shuffled=0.02, R^2 epigenetic regulators shuffled=0.01) (**Figure 2A**). 181 Furthermore, the selected models identified a small set of informative epigenetic regulator 182 genes and TEs associated with the identified immune types from a large number of genes and 183 TEs that were part of the model, i.e. signature features. Signature features with the highest 184 contribution to the model included the MER57F (ERV1), MER45A (DNA transposon), Tigger17a 185 (DNA transposon), MER61F (ERV1), LTR104 Mam (*Gypsy*), HERVL74.int (ERVL)

TE subfamilies, expression of which was significantly greater in the immune-hot cluster (**Figure 2B** and **2C**). In addition, *IKZF1*, a chromatin-interacting transcription factor⁴⁰ which regulates three-dimensional chromatin structure⁴¹, was the only epigenetic regulator of 532 genes tested as single genes to significantly contribute to the immune type prediction model and was associated with B cell infiltrates (**Figure 2B, 2C** and **Extended Data Figure 6A**).

191

192 We next fitted a logistic regression model using the signature features (i.e., *IKZF1* and TE score) 193 to predict their effect on immune type. To calculate a TE score, we combined the expression 194 values of the 6 signature feature TEs, for which expression of each of which was also positively 195 correlated (Extended Data Figure 6B). After adjusting for sequencing batch and histology, we 196 found that both TE score ($p=2.2 \times 10^{-3}$), and *IKZF1* expression ($p=5.8 \times 10^{-3}$), were significantly 197 associated with immune type. This suggests that IKZF1 and TE affect immune type. We used a 198 conditional independence approach (see Methods) to further investigate the potential causal 199 relationships between *IKZF1*, TEs, and immune type. Our analysis revealed that: a) given IKZF 200 expression, TE expression (TE score) is not conditionally independent of immune type (p=1.17 x 201 10⁻⁵), b) given TE expression, *IKZF1* expression is conditionally independent of immune type

- 202 (p=0.14), and c) TEs and *IKZF1* do not have an independent impact on immune type (p=2.35 x
- 203 10⁻⁶). This analysis suggests that TEs play a significant role in determining immune type, and that
- they interact with IKZF1 in a complex way to modulate the immune response.
- 205

High expression of TEs and *IKZF1* is associated with immune and inflammatory pathway

207 signatures and progression free survival

208 We next determined whether IKZF1 and TE expression correlated with activation of immune and 209 inflammatory pathways using a partial Pearson correlation. Both IKZF1 and TE score were 210 positively correlated with multiple immune pathways, while pathways related to non-immune 211 function were either significantly inversely correlated or not significantly correlated, suggesting a 212 distinct relationship between TEs and IKZF1 expression and immune activity in sarcomas (Figure 213 **3A**). Specifically, TE score and *IKFZ1* expression were significantly correlated with antiviral 214 response pathways such as cGAS-STING (TE score, $r^2=0.64$, $p=7.90 \times 10^{-9}$; *IKZF1*, $r^2=0.67$, 215 p=1.03 x 10⁻⁹), type I interferon (TE score, r²=0.38, p= 1.55 x 10⁻³, *IKZF1*, r²=0.32, p=7.89 x 10⁻³), 216 and type II interferon (TE score, $r^2=0.68$, $p=2.66 \times 10^{-10}$, *IKZF1*, $r^2=0.55 p=1.28 \times 10^{-6}$). Moreover, 217 we observed positive correlations between TE score and *IKZF1* expression and the upregulation 218 of antigen-processing machinery (TE score, $r^2=0.49$, $p=2.99 \times 10^{-5}$, *IKZF1*, $r^2=0.27$, $p=2.44 \times 10^{-5}$ 219 ²) as well as the CD8+ T cell effector pathway (TE score, $r^2=0.54$, $p=2.94 \times 10^{-6}$, IKZF1, $r^2=0.45$, 220 p=1.17 x 10⁻⁴).

221

Because *CD274* (PD-L1) expression was significantly higher in the immune-hot group (**Figure 1C**), we also investigated the association between immune checkpoint-related genes and immune activity and found a significant positive correlation between *CD274* and immune and inflammatory pathways (CD8+ T cell effector, r²=0.36, adjusted p= 3.21×10^{-3} , cGAS-STING, r²=0.71, p= 1.53 $\times 10^{-11}$; type II interferon, r²=0.54, p= 2.51×10^{-6}). TE score and *IKZF1* also positively correlated with *CD274* expression (p= 4.40×10^{-9} and p= 2.5×10^{-10} respectively) (**Figure 3B**). We next tested

228 whether the TE score and *IKZF1* expression were predictive of PFS. Both high TE score (p=1.65) 229 x 10⁻³) and *IKZF1* expression ($p=9.28 \times 10^{-3}$) correlated with prolonged PFS (high TE 4.4 months 230 vs. low TE 1.8 months; high *IKZF1* 5.3 months vs. low *IKZF1* 1.8 months) (Figure 3C). The ORR 231 based on *IKZF1* expression was 54.5% (6/11) in the high-expressing group and 10.7% (6/56) in 232 the low-expressing group ($p=2.72 \times 10^{-3}$; Fisher's exact test). ORR in the TE-high group was 40% 233 (6/15) and 11.53% (6/52) in the TE-low group (p=0.13; Fisher's exact test). Taken together, these 234 findings suggest that both IKZF1 expression and TE score, which were identified in model that 235 considered subtypes as a variable, could be explored as predictive biomarkers for ICI outcomes.

236

TE and *IKZF1* expression associate with immune infiltrate and inflammatory pathway activation in a separate validation cohort of sarcoma patients

239 To assess the replicability of our findings, we applied our analysis to gene expression data from 240 190 sarcoma samples from the TCGA³. This group was chosen as it includes 5 sarcoma subtypes. 241 DDLPS (n=49), MFS (n=17), LMS (n=80; 53 STLMS; 27 ULMS), and UPS (n=44), which were 242 prevalent in our original cohort. The immune signatures in the validation cohort segregated into 243 two distinct clusters marked by high (immune-hot) and low (immune-cold) immune infiltrates and 244 expression of immune checkpoints (Figure 4A-C, Extended Data Figure 7). The immune-hot 245 cluster was associated with improved overall survival ($p=1.09 \times 10^{-2}$), at a median of 37.5 months 246 vs. 25.5 months for the immune-cold cluster (Figure 4D).

247

As in the original cohort, expression of TEs and epigenetic regulators predicted immune type (Extended Data Figure 8A) and specific TEs and *IKZF1* were identified as signature features that positively correlated with immune-hot classification (Extended Data Figure 8B, C). Furthermore, expression of *IKZF1* and TEs (again defined as a composite TE score) correlated with that of immune pathways including type I and II interferon (p<0.001), antigen-processing machinery (p<0.001), and immune checkpoint genes (p<0.001) including *CD274*, but not non-

immune pathways (**Extended Data Figure 9A, B**). Overall survival was greater for patients whose tumor had a high TE score ($p=1.26 \times 10^{-3}$) or *IKZF1* ($p=4.94 \times 10^{-3}$) expression (**Figure 4E, F**).

- 256
- 257

258 Discussion

259 To address the pressing need to identify predictive biomarkers of response to ICI-based therapy 260 in sarcomas, we identified the minimal number of immune clusters that represent immune-hot and 261 -cold sarcomas and showed that the former is associated with higher ORR and longer PFS 262 following ICI treatment independent of subtype. This finding corroborates prior studies that have 263 shown a correlation between high baseline immune infiltrates and response to immune therapy¹⁹. 264 Importantly, our work demonstrates that these findings apply in a cohort with a broad spectrum of 265 sarcoma subtypes and in the setting of 3 combination ICI trials with diverse mechanisms. 266 Moreover, our analysis shows that a binary classification of tumors is sufficient to correlate with 267 clinical outcomes, indicating that immune clustering can be simplified compared to previous 268 approaches that involved more groups¹⁹. Such a simplified system could be helpful in smaller 269 studies with limited numbers of cases.

270

271 To identify specific tumor-intrinsic features that contribute to differences in immune states, we 272 focused on epigenetic regulation. Epigenetic mechanisms are known to suppress antitumor 273 immune responses and targeting epigenetic pathways has emerged as a promising therapeutic 274 strategy^{21,30,42}. Specifically, we examined the expression of epigenetic regulators and TEs, the 275 latter of which are normally epigenetically silenced (e.g., via establishment of heterochromatin) 276 and can stimulate innate immune responses when de-repressed^{27-29,43}. We observed increased 277 expression of TEs in immune-hot tumors. This is consistent with the ability of TEs to activate 278 dsRNA-sensing pathways, as has been observed in the setting of genetic lesions in epigenetic

regulators or pharmacologic treatment that lead to their de-repression^{23,24,30,44}. Our observation of upregulated antiviral immune responses (including cGAS and type I interferon signaling) and antigen-presenting pathways is consistent with this mechanism. Further investigation is needed to determine whether the presentation of TE-derived neoantigens via MHC-I, as observed in the loss of epigenetic TE silencing, could also contribute to the immune-hot state^{27,38}.

284

285 In addition to TEs, our analysis revealed that expression of *IKZF1* was significantly greater in 286 immune-hot tumors and associated with PD-L1 expression and B cell infiltrates, which was 287 validated in a separate cohort of 190 sarcoma samples from the TCGA. Notably, greater 288 infiltration of B lineage immune cells associates with overall survival in soft tissue sarcomas¹⁹. 289 Although Ikaros, the IKZF1 gene product, is primarily studied as a transcription factor in 290 hematologic lineages⁴⁰, it was included in our list of epigenetic regulators given the inherent 291 interaction of transcription factors and chromatin. Recent reports also suggest an important role 292 for Ikaros in regulating higher order chromatin structure⁴¹. Notably, previous studies have 293 determined that if IKZF1 is expressed in tumor cells and not only in immune populations, it 294 contributes to upregulation of immune infiltration and enhances the efficacy of anti-PD-1 and anti-295 CTLA-4 immunotherapies in murine models⁴⁵. Our findings raise the possibility of a similar effect 296 in sarcomas.

297

It is unclear whether TE de-repression and *IKZF1* expression are directly linked mechanistically. One possibility is that IKZF1 regulates TE expression, as several TE families contain an IKZF1binding motif⁴⁶. It is also possible that the mechanism for loss of epigenetic silencing at TEs creates a permissive chromatin state for *IKZF1* binding that allows for activation of nearby genes involved in innate immune activation. Alternatively, de-repression of TEs, which can act as cisregulatory elements, could promote *IKZF1* expression. In our study, conditional independence

analysis supports a model in which IKZF1 regulates TE expression, which in turn
 determines immune types. However, functional studies are needed to test this hypothesis.

306

307 There are several limitations of this study including the relatively small sample size (n=67), the 308 heterogeneity in sarcoma subtypes, and that patients were included from 3 trials of ICI-based 309 regimens with different mechanisms. However, while this heterogeneity may have decreased our 310 ability to identify signals related to specific epigenetic genes or TE families, we were reassuringly 311 able to classify tumors into immune classes that were predictive of clinical outcomes and confirm 312 prior classification systems. Furthermore, our key findings were confirmed in a larger validation 313 cohort (n=190), which included common sarcoma subtypes also represented in the original 314 sample set. However, the validation cohort differed in that samples were from patients who had 315 not received systemic therapy, it was composed of nearly all primary tumors, and outcome was 316 overall survival and not PFS or response following ICI-based treatment. Another caveat of the 317 study is that we selected polyadenylated transcripts for RNA sequencing, which would limit 318 detection of theoretically transcribed but non-polyadenylated TEs. We were also potentially limited 319 by considering epigenetic genes as independent, when many encode proteins that form 320 complexes or functional pathways.

321

Increasing the effectiveness of immunotherapies and identifying predictors of ICI response would both represent important advances in sarcoma. Our work presents several possibilities for achieving these goals using data from pretreatment biopsies. We confirm earlier studies showing that pretreatment immune status can predict ICI outcomes and propose *IKZF1* expression and TE score as potential predictive biomarkers for ICI response, both of which require validation. In addition, this work reveals potential avenues to enhance ICI response through stimulation of immune responsiveness of baseline immune-cold tumors to convert them into an immune-hot

- 329 phenotype. Based on this work, promoting the de-repression of TEs by pharmacologic targeting
- 330 of epigenetic regulators could be explored in preclinical models.
- 331
- 332

333 Materials and Methods

Clinical data were collected and DNA and RNA sequencing of pre-treatment biopsy samples was performed under Institutional Review Board oversight of 3 clinical trials performed at the Memorial Sloan Kettering Cancer Center. These include pembrolizumab plus talmogene laherparepvec (NCT03069378)³³, nivolumab plus bempegaldesleukin (NCT03282344)², and pembrolizumab plus epacadostat (NCT03414229)³⁴. Details regarding each study's design, safety oversight, and interventions can be found in referenced publications for each study.

340

341 Samples

A total of 67 baseline samples from twelve sarcoma subtypes (angiosarcoma (ANGS) =4, alveolar soft part sarcoma (ASPS)=1, chondrosarcoma (CHS)=6, epithelioid hemangioendothelioma (EHE)=8, leiomyosarcoma (LMS)=11, liposarcoma (LPS)=8, myxofibrosarcoma (MFS)=2, osteosarcoma (OS)=4, Other=7, sarcoma not otherwise specified (SARCNOS)=2, small blue round cell sarcoma (SBRC)=4, and undifferentiated pleomorphic sarcoma (UPS)=8, representing twelve responders and 55 non-responders (CR/PR=12, SD=21, PD=34) were transcriptionally profiled (**Extended Data Table 1**).

349

350 **RNA** sequencing, and quantification of TEs and genes

After quantification of RNA using RiboGreen and quality control using the Agilent BioAnalyzer,
 469-500 ng of total RNA with RNA integrity values ranging from 6.8–10 underwent polyA selection
 and TruSeq library preparation following the instructions provided by Illumina (TruSeq Stranded

mRNA LT Kit, catalog #RS-122-2102), with 8 cycles of PCR. The resulting samples were barcoded and run on a HiSeq 4000 at 100 paired-end reads, using the HiSeq 3000/4000 SBS Kit (Illumina), generating an average of 41 million paired reads per sample. Ribosomal reads represented 0.9–5.9% of the total reads generated and the percent of mRNA bases averaged 64%.

359

360 The obtained FASTQ files were processed using the REdiscoverTE³⁸ workflow, which allowed for 361 quantification based on transcript levels. Gene transcripts were aggregated to obtain individual 362 gene quantification. Read counts for each individual transposable element (TE) were then 363 gathered to the level of TE subfamily, family, and class, as defined by the human Repeatmasker 364 Hg38. TE expression was further divided into inter- and intragenic regions as defined by Gencode 365 GTF/GFF and implemented in REdiscoverTE. Downstream analysis considered only intergenic 366 expression of 1002 out of a total of 1052 TE subfamilies that were expressed. Gene-based 367 normalization factors were calculated using the 'RLE' algorithm in edgeR⁴⁷, as determined by 368 REdiscoverTE. The data was further variance-stabilized using the voom function from edgeR.

369

370 **RNAseq deconvolution and generation of immune clusters**

We quantified immune cell populations from variance-stabilized RNAseq data using the immunedeconv R package and its deconvolute function, along with the MCPcounter option 3.6.3³¹. Batch effects due to sequencing run were removed using removeBatchEffect() function from the limma R package⁴⁸. To reduce the dimensionality of the immune cell proportion data, we first performed a principal component analysis, followed by hierarchical clustering on principal components (HCPC) using the FactoMineR package ⁴⁹. Cluster types were visualized using the factoextra R package (https://CRAN.R-project.org/package=factoextra).

378

Heatmaps of expression in each cluster were generated based on the scaled (Z-scores) immune cell proportions. Z-scores were calculated using the formula $z = (x-\mu)/\sigma$, where x is the raw cell fraction, μ is the mean of all samples, and σ is the standard deviation for all samples.

382

383 To obtain the cellularity enrichment scores for 64 cell types, from which lymphoid and myeloid cell 384 type proportions can be derived, we used the xCellAnalysis function in the xCell R package 385 (https://github.com/dviraran/xCell). Total lymphoid content was calculated as the sum of 21 386 lymphoid cell scores, including CD8 + T cells, NK cells, CD4 + naive T cells, B cells, CD4 + T cells, 387 CD8+ Tem, Tregs, plasma cells, CD4 + Tcm, CD4+ Tem, memory B cells, CD8+ Tcm, naive B-388 cells, CD4+ memory T cells, pro B cells, class-switched memory B cells, Th2 cells, Th1 cells, 389 CD8+ naive T cells, NKT, and Tgd cells. Total myeloid content was expressed as the sum of 13 390 cell scores, including monocytes, macrophages, dendritic cells (including activated, conventional, 391 interstitial, and plasmacytoid), neutrophils, eosinophils, M1 macrophages, M2 macrophages, 392 basophils, and mast cells.

393

To test if immune type predicts survival in sarcoma, we performed Cox regression analysis that included histology to control for subtype-specific differences in outcomes. We compared survival between groups using the Kaplan-Meier survival curve and the Cox proportional-hazards regression mode. Differences were considered significant if the p-value was less than 0.05 for the tested group.

399

400 Exome sequencing and purity estimation

401 Viably frozen cells were thawed and pelleted and incubated for at least 30 min in 360 μ L Buffer 402 ATL + 40 μ L proteinase K at 55°C. DNA was isolated using the DNeasy Blood & Tissue Kit 403 (QIAGEN catalog #69504) according to the manufacturer's protocol with 1 h of incubation at 55°C 404 for digestion. DNA was eluted in 0.5X Buffer AE.

405

406 After PicoGreen quantification and quality control by Agilent BioAnalyzer, 100-250 ng of DNA was 407 used to prepare libraries using the KAPA Hyper Prep Kit (Kapa Biosystems KK8504) with 8 cycles 408 of PCR. After sample barcoding, 100-500 ng of library DNA was captured by hybridization using 409 the xGen Exome Research Panel v1.0 (IDT) according to the manufacturer's protocol. Post-410 capture libraries were amplified using 8 PCR cycles. Samples were run on a HiSeq 4000 at 100 411 paired-end reads using the HiSeq 3000/4000 SBS Kit (Illumina). Normal and tumor samples were 412 covered to an average of 102X and 219X, respectively.

413

414 FASTQ files were aligned and processed using the in-house workflow Tempo 415 (https://github.com/mskcc/tempo)⁵⁰. Briefly, reads were aligned using Burroughs-Wheeler Aligner 416 (BWA)-MEM ⁵¹ to the GRCh37 reference genome and base recalibration was performed using 417 Genome Analysis Toolkit (GATK) best practices. Somatic genome variants were called using the 418 union of Mutect2 and Strelka2. Variants were then filtered based on the following criteria: tumor 419 read depth of 20, variant allele frequency < 0.5 x the tumor alternate read count of 3, and normal 420 read depth of 10. In addition, repeated regions from RepeatMasker⁵² and variants that appear at 421 allele frequencies >0.01 in GNOMAD⁵³ were filtered out. Somatic copy number alterations were 422 analyzed using FACETS (Fraction and Allele-Specific Copy Number Estimates from Tumor 423 Sequencing) v0.5.14⁵⁴. Each tumor and matched normal pair was processed in two steps: a first 424 run for ploidy and purity estimation followed by a second run for detection of focal events. Each 425 fit was reviewed manually to minimize false positives and to estimate the quality of the fit. Purity 426 estimates from facets were used in the subsequent analysis.

427

428 Lasso association between immune types and genomic features

429 To identify genomic features that significantly differed between the two immune types, we used lasso logistic regression via penalized maximum likelihood using the R package glmnet⁵⁵. To 430 431 account for potential variations due to sequencing batch or subtypes, we included these 432 parameters in the basic model. Other models were further built with either normalized expression of 1002 intergenic TEs, shuffled TE expression, normalized expression of epigenetic modulators 433 434 (532 genes), or shuffled epigenetic modulator expression. 435 1. Basic model: Immune types~ batch + sarcoma subtypes 436 2. Basic model + TE: Immune types~ batch + sarcoma subtypes + 1002 TEs 437 3. Basic model + TE shuffled: Immune types~ batch + sarcoma subtypes + 1002 TEs 438 shuffled 439 4. Basic model + epigenetic genes: Immune types \sim batch + sarcoma subtypes + 532 440 epigenetic genes 441 5. Basic model + epigenetic genes shuffled: Immune types~ batch + sarcoma subtypes + 442 532 epigenetic genes shuffled 443 TEs in the models represent intergenic TEs, and shuffled TE or epigenetic genes data represents 444 randomly assigned TE or epigenetic genes expression to the samples. 445 446 Tenfold cross-validation was performed for each regression, and lasso coefficients at one 447 standard error of the minimum mean cross-validation errors (lambda 1se) were used. Each lasso 448 fit returned a small number of predictors, i.e. variables with non-zero coefficients, matching 449 genomic features with significant contributions to difference between the two immune types. 450 R^2 values for each model were calculated from the fraction of deviance explained and averaged 451 across the 10 rounds of cross-validation. R^2 values were then used to determine the model with 452 the best performance. To identify notable features associated with immune type, we extracted 453 non-zero coefficients of the final best models.

454

To further test the relationship between significant TE and epigenetic features determined by the glmnet model, we used logistic glm regression in which immune type represented a dependent variable, while TE score and *IKZF1* expression represented independent variables. The model was corrected for batch and histology covariates. The TE score was calculated by generating a z-score for the expression of 8 TEs found to be significant in the glmnet analysis and that exhibited positive correlation with each other (**Extended Data Figure 6B**). Z-score was generated using the gsva function of the GSVA package⁵⁶.

462

463 Logistic regression and conditional independence test

To further confirm the relationship between selected TEs and *IKZF1* expression with respect to immune cluster, we performed a logistic regression test. TE score and *IKZF1* were used as independent variables to assess their association with immune type. Bach and histology were used as covariates in the model.

468

469 Conditional independence (mutual information) tests to identify causal relationships between TEs,

470 IKZF1, and immune-hot/-cold phenotype were performed using the bnlearn package in R

471 (<u>https://www.bnlearn.com/</u>). Three hypotheses were tested:

- 472 a) TE score -> *IKZF1*-> Immune type: Immune type is conditionally independent of TE given
 473 *IKZF1*; TEs regulate *IKZF1* and do not directly regulate immune type.
- b) *IKZF1->* TE score -> Immune type: Immune type is conditionally independent of *IKZF1*given TE; *IKZF1* regulates TEs and does not directly regulate immune type.
- 476 c) *IKZF1->* Immune type <- TE score: *IKZF1* and TEs are conditionally independent of 477 immune type.
- 478

479 Gene signature calculations

Genes for immune/inflammatory and other signatures used to determine the correlation of significant features found to be predictive of immune type were defined as previously described in literature and summarized in Kong et al.³⁸ (except the cGAS pathway, which was downloaded from KEGG

484 <u>https://www.gseamsigdb.org/gsea/msigdb/cards/</u>). The ssGSEA algorithm was used to 485 comprehensively assess gene signature expression of each⁵⁷. The correlation between gene 486 signatures and normalized expression of significant features was assessed by partial Pearson 487 correlation analysis with batch and histology as covariates. P values were corrected using the 488 Benjamini-Hochberg correction.

489

490 **Comparison with previously reported immune classes**

491 To compare our immune clusters with formerly derived 5 sarcoma immune classes (SIC) 492 previously defined by Petitprez et al.,¹⁹ we obtained centroid infiltration scores for each of 4 cell 493 types (i.e. T cells, cytotoxic scores, B lineage, endothelial cells) of the 5 clusters derived from 494 MCP-counter analysis from the authors of the paper. We then calculated Euclidian distance 495 (distance = $\sqrt{\Sigma}(A_i-B_i)^2$) between centroids of four cell types (i.e. T cells, cytotoxic scores, B lineage, 496 endothelial cells) from each SIC (i.e. A,B,C,D,E) and the Z-score scaled MCP-counter proportions 497 from the same four cell types in our data. Each sample was assigned to SIC type based on the 498 lowest Euclidian distance with the 4 centroid infiltration scores for each SIC. Z-score-scaled 499 immune cell proportions were then plotted using the Complex heatmap package in R, and the 500 comparison with our Immune hot and cold clusters was performed.

501

502 **TCGA data analysis**

503 RNA sequencing data and phenotypic information were obtained from dbGaP for 190 TCGA 504 samples from 5 sarcoma subtypes, including DDLPS (n=49), MFS (n=17), LMS (n=80; 53 STLMS 505 +27 ULMS), and UPS (n=44). The REdiscoverTE pipeline was used to quantify gene and TE

506 expression. Batch effect information was downloaded from the TCGA Batch Effects Viewer 507 (https://bioinformatics.mdanderson.org/public-software/tcga-batch-effects/) and considered in the 508 subsequent data analysis. RNA sequencing was deconvoluted, immune clusters identified, and 509 lasso associations between immune types and genomic features and overall survival were 510 analyzed as described above. For the Kaplan- Meier analysis of this dataset our Cox regression 511 analysis included histology and tumor size. The latter was included since the TCGA dataset 512 comprises nearly all primary cases in which tumor size can be an more important prognostic 513 factor.

514

515 **Data Availability**

All RNA sequencing data, where informed consent has been obtained from the patient, is publicly available via dbGaP (accession number: phs003284). Three samples are not publicly available due to lack of consent for their release. All exome recapture sequencing data will be available via dbGaP under accession number phs001783 by the time of publication.

520

521 Code Availability

- 522 Custom code used for analysis is publicly available here:
- 523 <u>https://github.com/BradicM/Sarcoma_TE_paper_analysis</u>
- 524

525 Acknowledgements

526 This work was supported by Merck, Amgen, NEKTAR, Incyte, Bristol Myers Squibb, Cycle for 527 Survival, and Witherwax Fund. BAN received support from the NCI K08CA245212, the 528 Connective Tissue Oncology Society Basic Science Research Award (with WDT), and the Damon 529 Runyon Clinical Investigator Award. Additional support was provided by the Memorial Sloan 530 Kettering Cancer Center Support Grant (P30 CA008748) and Hillman Cancer Center Support 531 Grant (P30 CA047904) provided additional support. We acknowledge the use of the Integrated

Genomics Operation Core, funded by the NCI Cancer Center Support Grant (CCSG, P30
CA08748), and the Marie-Josée and Henry R. Kravis Center for Molecular Oncology.

534

535 **Competing Interests**

536 Sujana Movva: research funding from Ascentage Pharma, Tracon, Hutchinson Medi-pharma, 537 Pfizer/Trillium and research support from Merck, Clovis, and Bristol Meyers Squibb. Jason Chan: 538 research support from Ono pharmaceuticals. Mark Dickson: Research funding (to institution) from 539 Eli Lilly, Aadi Bioscience, and Sumitomo Pharma. Mrinal Gounder: Personal Honoraria/Advisory 540 Boards and/or Associated Research Paid to Institution from Aadi, Ayala, Bayer, Boehringer 541 Ingelheim, Daiichi, Epizyme, Karyopharm, Regeneron, Rain, Springworks, Tracon and TYME; 542 OTHER: Guidepoint, GLG, Third Bridge; Flatiron Health CME Honoraria: Medscape, More Health, 543 Physicians Education Resource, MJ LifeSciences and touchIME; ROYALTIES: Wolters Kluwer; 544 patents with MSKCC (GODDESS PRO); uncompensated research with Foundation Medicine 545 GRANTS from Food and Drug Administration (R01 FD005105) and the National Cancer Institute, 546 National Institutes of Health (P30CA008748)—core grant (CCSG shared resources and core 547 facility). Ping Chi: personal honoraria/advisory boards/consulting from Deciphera, NingboNewBay 548 Medical Technology; institutional research funding from Pfizer/Array, Deciphera, Ningbo NewBay 549 Medical Technology. Robert Maki: consulting fees from AADi, Bayer, Deciphera, Presage, 550 Springworks, American Board of Internal Medicine, American Society for Clinical Oncology and 551 UptoDate. Ciara Kelly: Institutional research funding from Merck, Amgen, Servier, Regeneron, 552 Xencor, Curadev pharma; Consulting for Kartos pharmaceuticals, Deciphera. Sandra D'Angelo: 553 Consulting or Advisory Role for Aadi Bioscience Adaptimmune, Adicet Bio, GI Innovations, 554 GlaxoSmithKline, Incyte, Medendi, Medidata, Nektar, Pfizer, Rain Therapeutics, Servier; 555 Research Funding from EMD Serono, Amgen, Merck, Incyte, Nektar, Britsol-Meyers Squibb, 556 Deciphera; Travel, Accommodations, Expenses from Adaptimmune, EMD Serono, Nektar; 557 Participation on a DataSafety Monitoring Board or Advisory Board for GlaxoSmithKline, Nektar,

558 Adaptimmune, Merck. William Tap: Consulting, Advisory Role, Honoraria: Aadi Biosciences, 559 Abbisko, Amgen, AmMAx Bio, Avacta, Ayala Pharmaceuticals, Bayer, BioAlta, Boehringer 560 Ingelheim, C4 Therapeutics, Cogent Biosciences, Curadev, Daiichi Sankyo, Deciphera, Eli Lilly, 561 Epizyme Inc (Nexus Global Group), Foghorn Therapeutics, Ikena Oncology, IMGT, Inhirbix Inc., 562 Ipsen Pharma, Jansen, Kowa Research Inst., Medpacto, Novo Holdings, PER, Servier, Sonata 563 Therapeutics; research funding from Novartis, Eli Lilly, Plexxikon, Daiichi Sankyo, Tracon 564 Pharma, Blueprint Medicines, Immune Design, BioAlta, Deciphera; Patents, Royalties, Other 565 Intellectual Property: Companion Diagnostics for CDK4 inhibitors (14/854,329), Stock and Other 566 Ownership Interests: Certis Oncology Solution, Atropos. All other authors declare no competing 567 interests. 568 569 **Extended Data Tables** 570 571 Extended Data Table 1. Patient and sample characteristics. 572 573 Extended Data Table 2. Summary of cell type contribution to two immune clusters 574 resulting from hierarchical clustering of principal components (HCPC) analysis. Overall 575 mean of cell proportion per cluster. 576 577 Extended Data Table 3. Summary of immune type counts and clinical responses per 578 clinical protocol. P values derived by Fisher's exact test. 579

580 **References**

581

- 582 1. WHO. Soft tissue and bone tumours, (International Agency for Research on Cancer,
- 583 Lyon (France), 2020).
- 584 2. D'Angelo, S.P., *et al.* Pilot study of bempegaldesleukin in combination with nivolumab in
- 585 patients with metastatic sarcoma. *Nat Commun* **13**, 3477 (2022).
- 586 3. Cancer Genome Atlas Research, N. Comprehensive and Integrated Genomic
- 587 Characterization of Adult Soft Tissue Sarcomas. *Cell* **171**, 950-965 e928 (2017).
- Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2018. *CA Cancer J Clin* 68, 7-30
 (2018).
- 590 5. von Mehren, M., *et al.* Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice
 591 Guidelines in Oncology. *J Natl Compr Canc Netw* **20**, 815-833 (2022).
- 592 6. Seddon, B., et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment
- 593 in previously untreated advanced unresectable or metastatic soft-tissue sarcomas
- (GeDDiS): a randomised controlled phase 3 trial. *The Lancet Oncology* 18, 1397-1410
 (2017).
- 596 7. D'Angelo, S.P., *et al.* Nivolumab with or without ipilimumab treatment for metastatic
 597 sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2
 598 trials. *The Lancet Oncology* **19**, 416-426 (2018).
- 599 8. Tawbi, H.A., *et al.* Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma
 600 (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. *The Lancet*601 Oncology 18, 1493-1501 (2017).
- Banks, L.B. & D'Angelo, S.P. The Role of Immunotherapy in the Management of Soft
 Tissue Sarcomas: Current Landscape and Future Outlook. *J Natl Compr Canc Netw* 20,
 834-844 (2022).

- 605 10. Carbone, D.P., *et al.* First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung
 606 Cancer. *N Engl J Med* 376, 2415-2426 (2017).
- Hellmann, M.D., *et al.* Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor
 Mutational Burden. *N Engl J Med* **378**, 2093-2104 (2018).
- 609 12. Rosenberg, J.E., *et al.* Atezolizumab in patients with locally advanced and metastatic
- 610 urothelial carcinoma who have progressed following treatment with platinum-based
- 611 chemotherapy: a single-arm, multicentre, phase 2 trial. *The Lancet* **387**, 1909-1920
- 612 (2016).
- 613 13. Van Allen, E.M., *et al.* Genomic correlates of response to CTLA-4 blockade in metastatic
 614 melanoma. *Science* **350**, 207-211 (2015).
- 615 14. Rizvi, N.A., *et al.* Cancer immunology. Mutational landscape determines sensitivity to
- 616 PD-1 blockade in non-small cell lung cancer. *Science* **348**, 124-128 (2015).
- 617 15. Samstein, R.M., *et al.* Tumor mutational load predicts survival after immunotherapy
 618 across multiple cancer types. *Nat Genet* **51**, 202-206 (2019).
- 619 16. Le, D.T., *et al.* Mismatch repair deficiency predicts response of solid tumors to PD-1
 620 blockade. *Science* 357, 409-413 (2017).
- 17. Nacev, B.A., *et al.* Clinical sequencing of soft tissue and bone sarcomas delineates
 diverse genomic landscapes and potential therapeutic targets. *Nat Commun* 13, 3405
 (2022).
- 18. Italiano, A., et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid
- 625 structures: a phase 2 PEMBROSARC trial cohort. *Nat Med* 28, 1199-1206 (2022).
- Petitprez, F., *et al.* B cells are associated with survival and immunotherapy response in
 sarcoma. *Nature* **577**, 556-560 (2020).
- Allis, C.D., Caparros, M.-L., Jenuwein, T. & Reinberg, D. *Epigenetics*, (CSH Press, Cold
 Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2015).

- 630 21. Que, Y., et al. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor
- chidamide and PD-1 blockade combination in soft tissue sarcoma. *J Immunother Cancer*9(2021).
- 633 22. Krug, B., et al. Pervasive H3K27 Acetylation Leads to ERV Expression and a
- 634 Therapeutic Vulnerability in H3K27M Gliomas. *Cancer Cell* **35**, 782-797 e788 (2019).
- 635 23. Chiappinelli, K.B., et al. Inhibiting DNA Methylation Causes an Interferon Response in
- 636 Cancer via dsRNA Including Endogenous Retroviruses. *Cell* **162**, 974-986 (2015).
- 637 24. Topper, M.J., *et al.* Epigenetic Therapy Ties MYC Depletion to Reversing Immune
- 638 Evasion and Treating Lung Cancer. *Cell* **171**, 1284-1300 e1221 (2017).
- 639 25. Sheng, W., et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables
- 640 Checkpoint Blockade. *Cell* **174**, 549-563.e519 (2018).
- 641 26. Macfarlan, T.S., *et al.* Endogenous retroviruses and neighboring genes are coordinately 642 repressed by LSD1/KDM1A. *Genes & amp: Development* **25**, 594-607 (2011).
- 643 27. Griffin, G.K., *et al.* Epigenetic silencing by SETDB1 suppresses tumour intrinsic
 644 immunogenicity. *Nature* (2021).
- 28. Zhang, S.M., *et al.* KDM5B promotes immune evasion by recruiting SETDB1 to silence
 retroelements. *Nature* **598**, 682-687 (2021).
- Hu, H., *et al.* Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by
 Boosting Tumor Immunogenicity. *Cancer Immunol Res* 9, 1298-1315 (2021).
- 649 30. Burr, M.L., et al. An Evolutionarily Conserved Function of Polycomb Silences the MHC
- 650 Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. *Cancer* 651 *Cell* 36, 385-401 e388 (2019).
- 652 31. Sturm, G., *et al.* Comprehensive evaluation of transcriptome-based cell-type
- 653 quantification methods for immuno-oncology. *Bioinformatics* **35**, i436-i445 (2019).
- 654 32. Lê S, J.J., Husson F. FactoMineR: A Package for Multivariate Analysis. *Journal of*
- 655 Statistical Software **25**, 1–18 (2008).

- 656 33. Kelly, C.M., Antonescu, C. R., Bowler, T., Munhoz, R., Chi, P., Dickson, M. A., Gounder,
- 657 M. M., Keohan, M. L., Movva, S., Dholakia, R., Ahmad, H., Biniakewitz, M., Condy, M.,
- 658 Phelan, H., Callahan, M., Wong, P., Singer, S., Ariyan, C., Bartlett, E. K., Crago, A.,
- 659 Yoon, S., Hwang, S., Erinjeri, J.P., Qin, L.X., Tap, W.D., D'Angelo, S. P. Objective
- 660 Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated
- 661 With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2
- 662 Clinical Trial. . *JAMA Oncol*, 402-408 (2020).
- Kelly, C.M., *et al.* A Phase II Study of Epacadostat and Pembrolizumab in Patients with
 Advanced Sarcoma. *Clin Cancer Res* 29, 2043-2051 (2023).
- 665 35. Eisenhauer, E.A., *et al.* New response evaluation criteria in solid tumours: revised
- 666 RECIST guideline (version 1.1). *Eur J Cancer* **45**, 228-247 (2009).
- 667 36. Grundy, E.E., Diab, N. & Chiappinelli, K.B. Transposable element regulation and
 668 expression in cancer. *FEBS J* 289, 1160-1179 (2022).
- Anwar, S.L., Wulaningsih, W. & Lehmann, U. Transposable Elements in Human Cancer:
 Causes and Consequences of Deregulation. *Int J Mol Sci* 18(2017).
- 671 38. Kong, Y., *et al.* Transposable element expression in tumors is associated with immune
- 672 infiltration and increased antigenicity. *Nat Commun* **10**(2019).
- 673 39. Griffin, G.K., *et al.* Epigenetic silencing by SETDB1 suppresses tumour intrinsic
 674 immunogenicity. *Nature* 595, 309-314 (2021).
- 675 40. Churchman, M.L. & Mullighan, C.G. Ikaros: Exploiting and targeting the hematopoietic
- 676 stem cell niche in B-progenitor acute lymphoblastic leukemia. *Exp Hematol* **46**, 1-8
- 677 (2017).
- Hu, Y., *et al.* Lineage-specific 3D genome organization is assembled at multiple scales
 by IKAROS. *Cell* **186**, 5269-5289 e5222 (2023).

- 680 42. Soldi, R., et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor
- 681 immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian
- 682 cancer. *PLOS ONE* **15**, e0235705 (2020).
- 43. Voon, H.P., *et al.* ATRX Plays a Key Role in Maintaining Silencing at Interstitial
- 684 Heterochromatic Loci and Imprinted Genes. *Cell Rep* **11**, 405-418 (2015).
- 685 44. Stone, M.L., *et al.* Epigenetic therapy activates type I interferon signaling in murine
- 686 ovarian cancer to reduce immunosuppression and tumor burden. *Proc Natl Acad Sci U S*
- 687 A **114**, E10981-E10990 (2017).
- 45. Chen, J.C., Perez-Lorenzo, R., Saenger, Y.M., Drake, C.G. & Christiano, A.M. IKZF1
- 689 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to
- 690 Immunotherapy. *Cell Syst* **7**, 92-103 e104 (2018).
- 691 46. Deniz, O., *et al.* Endogenous retroviruses are a source of enhancers with oncogenic
 692 potential in acute myeloid leukaemia. *Nat Commun* **11**, 3506 (2020).
- 693 47. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for
- differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139140 (2010).
- 696 48. Ritchie, M.E., *et al.* limma powers differential expression analyses for RNA-sequencing
 697 and microarray studies. *Nucleic Acids Res* 43, e47 (2015).
- 49. Barrero, M.J. Epigenetic Regulation of the Non-Coding Genome: Opportunities for
 699 Immuno-Oncology. *Epigenomes* 4(2020).
- 50. MIT. Tempo: CCS Research Pipeline for Whole-Genome and Whole-Exome Sequencing(2019).
- 51. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.(2013).
- 704 52. Smit, A.H., R; Green, P. RepeatMasker Open-4.0. (2013-2015).

- 53. Karczewski, K.J., *et al.* The mutational constraint spectrum quantified from variation in
 141,456 humans. *Nature* 581, 434-443 (2020).
- 707 54. Shen, R. & Seshan, V.E. FACETS: allele-specific copy number and clonal heterogeneity
- analysis tool for high-throughput DNA sequencing. *Nucleic Acids Res* **44**, e131 (2016).
- 55. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear
- 710 Models via Coordinate Descent. *J Stat Softw* **33**, 1-22 (2010).
- 56. Lee, E., Chuang, H.Y., Kim, J.W., Ideker, T. & Lee, D. Inferring pathway activity toward
- 712 precise disease classification. *PLoS Comput Biol* **4**, e1000217 (2008).
- 713 57. Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for
- 714 microarray and RNA-seq data. *BMC Bioinformatics* **14**, 7 (2013).



Figure 1. Clustering of immune cell fractions groups tumors into two distinct types. **A.** Color bars at the top of the heatmap label samples by response (SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response), and histological subtype. Angiosarcoma, ANGS; alveolar soft part sarcoma, ASPS; chondrosarcoma, CHS; epithelioid hemangioendothelioma, EHE; leiomyosarcoma, LMS; liposarcoma, LPS; myxofibrosarcoma, MFS; osteosarcoma, OS; sarcoma not otherwise specified, SARCNOS; small blue round cell sarcoma, SBRC; undifferentiated pleomorphic sarcoma, UPS. **B.** Heatmap of immune and stromal cell fractions and cytotoxicity score determined by MCP-counter Z-scores. **C.** Immune checkpoint gene expression Z-scores. **D.** Kaplan-Meier plot representing progression-free survival (PFS) probability of immune-hot and -cold types. Tick marks indicate censoring. The P values on the Kaplan-Meier plots represent that output from cox proportional model that includes histology as a covariate.



Figure 2. Transposable element and IKZF1 expression predict tumor immune groups. **A.** Comparison of lasso logistic regression model performances (R2) of the 5 tested models for prediction of immune type. P values determined by t-test; *** <2.2 x 10⁻¹⁶. **B.** Contribution of significant features from the TE and epigenetic models (models with the highest R2) represented as non-zero coefficients. The size and sign of contribution (coefficients) indicate the direction and strength of the feature's effect on the outcome (immune cluster). **C.** Violin plots of normalized expression of transcripts identified as significant features in the regression model in immune-hot and -cold clusters. ***, p<0.001 as determined by one sided t-test.



Figure 3. Immune pathway activation and progression-free survival following ICI treatment are associated with increased expression of multiple TE families and IKZF1. **A.** Heatmap of partial Pearson correlation including batch and histology as covariates. Scale from -1 (inverse correlation, blue) to 1 (positive correlation, red). Asterisks indicate Benjamini-Hochberg-corrected p-values: *p<0.05, ** p<0.01, *** p<0.001. **B.** Correlation between CD274 (PD-L1) gene expression and TE score, and CD274 and IKZF1 expression. **C.** Kaplan-Meier curves representing progression-free survival probability according to high vs. low TE scores and IKZF1 expression. The P values on the Kaplan-Meier plots represent that output from cox proportional model that includes histology as a covariate.



Figure 4. TE score and IKZF1 expression associate with improved survival in a validation cohort. A. Clustering of samples into immune-hot and immune-cold types. Color bar at top labels samples by histological subtype. DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcoma; MFS, myxofibrosarcoma; UPS, undifferentiated pleomorphic sarcoma. B. Heatmap of immune and stromal cell fractions and cytotoxicity score determined by MCP-counter Z-scores. **C.** Immune checkpoint gene expression Z-scores. **D.** Kaplan-Meier plot of overall survival probability of patients with immune-hot and -cold type tumors. **E-F.** Kaplan-Meier curves representing overall survival probability of high (red) and low (blue) **E.** TE scores and **F.** high (red) and (low) IKZF1 expression. The P values on the Kaplan-Meier plots represent that output from cox proportional model that includes histology and tumor size as covariates.



Extended Data Figure 1. Determination of immune clusters from MCP-counter-based immune-deconvoluted cell proportions. Factor map representing two clusters based on hierarchical clustering of principal components. Each dot represents an individual patient sample.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.02.24300710; this version posted January 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No lease allowed without permission.									
Immune_subtypes	Immune cold (N=37)	reference							
	Immune hot (N=30)	(0.22 - 0.84)					0.013 *		
Abbreviation for Figures	ANGS (N=6)	reference	I						
	ASPS (N=1)	5.07 (0.44 - 58.26)	r		-		0.192		
	CHS (N=6)	(0.70 ^{3.71} 19.73)					0.124		
	ЕНЕ <i>(N=8)</i>	3.64 (0.72 – 18.35)	F		a		0.118		
	LMS (N=11)	7.36 (1.53 - 35.34)		F		I	0.013 *		
	LPS (N=8)	4.36 (0.86 - 22.17)	F			-	0.076		
	MFS (N=2)	18.20 (2.29 - 144.84)		·			0.006 **		
	OS (N=4)	8.20 (1.29 - 52.20)		F			0.026 *		
	Other (N=7)	3.13 (0.60 - 16.35)		-			0.177		
	SARCNOS (N=2)	(0.23 - 31.78)	ı				0.423		
	SBRC (N=4)	8.85 (1.37 - 56.92)		F			0.022 *		
	UPS (N=8)	3.20 (0.54 - 18.95)		-			0.199		
# Events: 48; Global p-value (Log- AIC: 336.63; Concordance Index: 0.	Rank): 0.072562 .69	0.	2 0.5	1 2	5 10 20	0 50	100 200		

Extended Data Figure 2. Forest plots showing multivariable Cox regression analysis of contribution of immune cluster, histology, and clinical protocol to risk of progression. p-values calculated using Cox proportional hazards analysis (*, $p \le 0.05$).



Extended Data Figure 3. Hot and cold immune types are related to previously identified sarcoma immune classes. SIC types of each sample in study cohort as determined by the Euclidian distance between centroids of the proportions of 4 cell types (i.e., T cells, cytotoxic scores, B lineage, endothelial cells) between each SIC (i.e., A, B, C, D, E)19 and proportions in each sample. Color bars at top of heatmap label the samples by response, histological subtype, SIC, and immune type. Heatmap indicates immune cell fraction determined by MCP-counter Z-score.



Extended Data Figure 4. Immune infiltrates are inversely related to sample purity. **A.** Violin plot comparing tumor purity between the two immune types. **B.** Distribution of 10,000 permutations of tumor purity shuffling between "immune-cold" and "immune-hot. The histogram shows the simulated absolute permuted differences in means. The vertical red line represents the observed value for the original two samples (immune-cold and immune-hot). **C.** Correlation between purity, lymphoid content, and myeloid cell content. Scale from -1 (inverse correlation, blue), to 1 (positive correlation, red). Areas of circles represent the absolute value of corresponding correlation coefficients.



Extended Data Figure 5. TE expression is heterogenous across sarcoma samples. Expression of all 1002 intergenic TEs expressed in the studied samples. Color bars at top of heatmap label the samples by response and histological subtype. Color bar at right labels repeat classes; LINE- Long interspersed nuclear elements, LTR-long terminal repeats, SINE- short interspersed nuclear elements. TE expression represented as Z- score; batch effect was removed.



Extended Data Figure 6. Correlation between IKZF1 expression and B cell infiltrates and between eight significant TEs detected in our model. **A.** Correlation between IKZF1 expression and B cell infiltrates. **B.** Pearson correlation among expression of 6 TEs. Scale from -1 (inverse correlation, blue) to 1 (positive correlation, red). Areas of circles represent the absolute value of corresponding correlation coefficients.



Extended Data Figure 7. Determination of immune clusters from MCP-counter-based immune deconvoluted cell proportions in the TCGA cohort. Factor map representing two clusters based on hierarchical clustering of principal components. Each dot represents an individual patient sample.



Extended Data Figure 8. TEs and IKZF1 expression predict immune groups in the TCGA cohort. **A.** Comparison of performances (R2) of 5 lasso logistic regression model models. Each boxplot represents a different model (basic model, bootstraped basic model + TE, and bootstraped basic model + Epigenetic genes (EPI), and error bars represent 95% confidence intervals. Shuffled models for TE and EPI are also shown. Difference between bootstraped and shuffled model is shown as result of t-test (***, p-value < 2.2e-16). **B.** Contribution of significant features from the TE and epigenetic genes (italicized) are shown. **C.** Violin plots of normalized expression of transcripts identified as significant features in the regression model in immune-hot and -cold clusters. *** represents p<0.001 as determined by two-sided t-test.



Extended Data Figure 9. TEs and IKZF1 expression correlate with immune pathway expression in the TCGA cohort. **A.** Heatmap of partial Pearson correlation including batch and histolotgy as covariates. Scale from -1 (inverse correlation, blue), to 1 (positive correlation, red). Asterisks indicate Benjamini-Hochberg-corrected p-values: * p<0.05, ** p<0.01, *** p<0.001. **B.** Correlation between CD274 (PD-L1) gene expression and TE score (top) and IKZF1 expression (bottom).).